Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Enabling patient PRPs

Mercator strikes two deals to optimize its peptide-receptor pairs in cancer

After securing exclusive rights to an in vivo, patient-based screening platform for cancer-specific peptide-receptor pairs, Mercator Therapeutics Inc. needed a source of optimized peptides and antibodies. A pair of deals this month gives the biotech access to antibodies for targeting the receptors, and peptides for delivering toxins to tumors.

Mercator was founded in 2010 to commercialize the work of Renata Pasqualini and Wadih Arap, two researchers from the University of Texas M.D. Anderson Cancer Center who have spent more than a decade developing patient-based

Read the full 833 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE